fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2006-02-07
Biotech partner: Hybrigenics (France) The Universities of Leuven and Ghent (both Belgium)
Pharma Partner:  
Type of agreement: * licensing
Compound: inecalcitol in all its therapeutic indications
Disease area: Two development axes for this vitamin D analogue: (i) oncology and notably hormone therapy- refractory prostate cancer, (ii) psoriasis and hyperparathyroidism, in collaboration with Theramex.
Development phase:  
Nature of the agreement:  
Financial terms of the agreement: not disclosed


Go back to previous page